Brainstorm Cell Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCLI research report →
Companywww.brainstorm-cell.com
Brainstorm Cell Therapeutics Inc. , a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
- CEO
- Chaim Lebovits
- IPO
- 2003
- Employees
- 27
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $7.95M
- P/E
- -0.83
- P/S
- 0.00
- P/B
- -0.72
- EV/EBITDA
- -1.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 109.21%
- ROIC
- 91.81%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-10,307,000 · -188.68%
- EPS
- $-1.11 · -150.68%
- Op Income
- $-9,953,000
- FCF YoY
- 23.29%
Performance & Tape
- 52W High
- $1.33
- 52W Low
- $0.46
- 50D MA
- $0.80
- 200D MA
- $0.68
- Beta
- 0.21
- Avg Volume
- 15.51K
Get TickerSpark's AI analysis on BCLI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 1, 25 | Dagher Ibrahim B. | other | 50,000 |
| Apr 17, 24 | Dagher Ibrahim B. | other | 0 |
| Apr 17, 24 | Dagher Ibrahim B. | other | 0 |
| Apr 17, 24 | Dagher Ibrahim B. | other | 0 |
| Apr 17, 24 | Dagher Ibrahim B. | other | 80,000 |
| Jan 1, 25 | Lebovits Chaim | other | 120,000 |
| Jan 1, 25 | FRENKEL JACOB A | other | 40,000 |
| Jan 1, 25 | Polverino Anthony J. | other | 24,000 |
| Jan 1, 25 | Yablonka Uri | other | 20,000 |
| Jan 1, 25 | Yablonka Uri | other | 40,000 |
Our BCLI Coverage
We haven't published any research on BCLI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BCLI Report →